

ARTICLE OPEN



Retinoic acid related orphan receptor α is a genetic modifier that rescues retinal degeneration in a mouse model of Stargardt disease and Dry AMD

M. Akula¹, S. M. McNamee¹, Z. Love¹, N. Nasraty¹, N. P. M. Chan¹, M. Whalen¹, M. O. Avola¹, A. M. Olivares¹, B. D. Leehy¹, A. S. Jelcick¹, P. Singh², A. K. Upadhyay², D. F. Chen¹ and N. B. Haider¹✉

© The Author(s) 2024

Degeneration of the macula is associated with several overlapping diseases including age-related macular degeneration (AMD) and Stargardt Disease (STGD). Mutations in ATP Binding Cassette Subfamily A Member 4 (*ABCA4*) are associated with late-onset dry AMD and early-onset STGD. Additionally, both forms of macular degeneration exhibit deposition of subretinal material and photoreceptor degeneration. Retinoic acid related orphan receptor α (*RORA*) regulates the AMD inflammation pathway that includes *ABCA4*, *CD59*, *C3* and *C5*. In this translational study, we examined the efficacy of *RORA* at attenuating retinal degeneration and improving the inflammatory response in *Abca4* knockout (*Abca4*^{-/-}) mice. AAV5-*hRORA*-treated mice showed reduced deposits, restored CD59 expression and attenuated amyloid precursor protein (APP) expression compared with untreated eyes. This molecular rescue correlated with statistically significant improvement in photoreceptor function. This is the first study evaluating the impact of *RORA* modifier gene therapy on rescuing retinal degeneration. Our studies demonstrate efficacy of *RORA* in improving STGD and dry AMD-like disease.

Gene Therapy; <https://doi.org/10.1038/s41434-024-00455-z>

INTRODUCTION

Age related macular degeneration (AMD) is a complex retinal degenerative disease that is a leading cause of central vision loss in older adults. AMD is multigenic, also impacted by environmental influences and only naturally occurring in humans [1–8]. Dry AMD is the most common form, accounting for about 90% of AMD cases, and involves formation of deposits in the subretinal and sub-retinal pigment epithelium (RPE) spaces, damaging the macula, which is required for clear central vision [9]. While AMD is typically diagnosed after age 65, it can occur as early as age 45 [refs. 10–12]. In contrast, Stargardt Disease (STGD), with an incidence rate of 1 in 8 000–10 000, is a juvenile form of macular degeneration that includes early onset vision loss starting as early as 10 years of age [13–18]. Vision loss is typically observed in the first decade of life; however, some patients do not begin to lose vision until adulthood [15, 19]. STGD results from a build-up of fatty material on the macula of the retina, and causes retinal degeneration and vision loss. The most common symptoms of STGD are a slow, bilateral loss of central vision, dark or hazy spots in the visual center [20], sensitivity to light [21], longer time to dark adaptation [22–24] and color blindness [25]. STGD patients also show complement system dysregulation in the RPE [26]. Recently, two new drugs, pegcetacoplan (Syfovre) [27] and avacincaptad pegol (Izervay) [28], were FDA approved to treat geographic atrophy secondary to dry AMD. Both of these drugs target specific genes in the complement and inflammatory

pathways. Pegcetacoplan is a complement C3 inhibitor requiring injection at least every other month; however, patients are at risk of developing exudative AMD following treatment (8.9%) compared to sham-treated eyes (1.2%) [ref. 27]. Similarly, avacincaptad pegol targeting complement C5 requires monthly injections, and patients treated with this drug had a 4–9.6% chance of developing choroidal neovascularization compared to 2.7% for sham-treated eyes [29]. Thus, there is great value in continuing to develop and test novel targets that can prevent or treat different pathways for dry AMD and STGD.

STGD and dry AMD have significant overlap in the clinical, molecular, and genetic phenotypes such as formation of deposits in the subretinal region, RPE cell damage, perturbations in the complement pathway and ATP Binding Cassette Subfamily A Member 4 (*ABCA4*) variants associated with each disease [13, 15–17, 26, 30–38]. Prior publications show that heterozygous *ABCA4* variants are associated with AMD, with one study suggesting that *ABCA4* mutations may be dominantly inherited in AMD [30–32, 39]. In contrast, the most common cause of STGD results from autosomal recessive mutations in the *ABCA4* gene [40–42]. Mutations in the *ABCA4* gene lead to faulty processing and transportation of all-trans retinaldehyde from photoreceptors to the RPE. Mutations in *ABCA4* cause accumulation of N-retinylidene-N-retinyl-ethanolamine (A2E), the main fluorophore found in lipofuscin forming deposits in the RPE [43]. STGD typically presents with progressive bilateral loss of central vision paired

¹Schepens Eye Research Institute, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA, USA. ²Ocugen, Inc., Malvern, PA, USA. ✉email: neena_haider@hms.harvard.edu




Fig. 1 RORA-regulated gene pathways. String pathway analysis demonstrates the relationship between ABCA4, RORA and CD59 in the inflammatory response and complement gene pathways regulated by *RORA*. Each node depicts a protein encoded by a gene, and each line represents an association between proteins. Node colors represent specific *RORA*-regulated pathways: angiogenesis is depicted in red, neuroprotection using indigo, the inflammatory response in light green, the complement cascade in dark green, lipofuscin formation in brown, oxidative stress in orange, lipid metabolism in yellow, phototransduction in pink and neurogenesis in mauve. Known interactions are shown using blue (curated databases), bright green (proteins mentioned in publications) or pink lines (experimentally determined proteins), while predicted interactions are shown in green (proteins in close proximity) or dark blue lines (co-occurring proteins).

with the appearance of subretinal lipofuscin flecks in the macula [44]. *ABCA4*-associated retinopathies manifesting early in life progress more rapidly, while a later age of onset is associated with a milder prognosis and can be misdiagnosed as age-related macular degeneration (AMD) [6, 42, 45].

Retinoic acid related orphan receptor α (*RORA*) is a nuclear hormone receptor (NHR) that regulates several homeostatic pathways in the retina including the lipid metabolism, oxidative stress and inflammation pathways [46–48]. Prior results demonstrated that *RORA* is linked with AMD and is a known regulator of multiple AMD genes [2, 48, 49]. Furthermore, pathway analysis by our lab shows that *RORA* regulates the inflammatory response pathway that includes *ABCA4* and *CD59* (Fig. 1). *CD59* is an inhibitor of membrane attack complex (MAC) which is assembled with the help of complement C3 and C5 proteins, both of which are implicated in STGD and AMD disease [26, 35, 36]. Thus, *RORA* has the potential to be a more powerful therapeutic as a regulator of AMD-associated genes. In the current study, we evaluate AAV5-*hRORA* as a modifier gene therapy for macular degeneration using the *Abca4*^{-/-} mouse displaying both the clinical and molecular phenotypes of dry AMD and STGD [22, 33, 43, 50].

MATERIALS AND METHODS

Animal use and ethics

This study was performed in accordance with the Guide for the Care and Use of Laboratory Animals of the National Institute of Health and the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research. *Abca4*^{-/-} (*Abca4*^{tm1Ght/J}, Stock #023725, Jackson Laboratories, Bar Harbor, ME, USA) mice and 129S1 (129S1/SvImJ, Stock #002448, Jackson Laboratories) wild type (WT) animals were housed under standard conditions at a temperature between 20 and 25 °C in a 12-h light and 12-h dark cycle. The Schepens Eye Research Institute Animal Care

and Use Committee approved all animals and procedures used for this study (Protocol Number: 2020N000178) in compliance with the regulations of the Animal Welfare Act.

Scientific rigor and reproducibility

A power calculation was conducted using G*Power 3.1 software analysis for estimating the sample size required for each type of analysis. Using the means and standard deviation defined by previously published studies, a minimum of five animals per experimental group were used to provide over 90% power and a 30% difference with a significance level set at 0.05. Every procedure was carried out using a standardized protocol. This study was conducted by several trained personnel in a double blinded and randomized way in order to prevent bias. Five biological replicates were used at a minimum for each dose and time point to reach statistical significance. Animals with unresolved surgical trauma, premature unintended death or cataracts, or data resulting from technical error were excluded from the study. Less than 10% of the 60 total treated experimental animals were excluded from all analyses based on these criteria. An equal number of males and females were used, as sex is not a biological variable in this study.

Statistics

The differences in the mean blue autofluorescence (BAF) levels, scotopic b-wave amplitudes, recovery of a-wave amplitudes, the number of cell layers in the ONL, and the mean *CD59* and *RORA* immunolabeling fluorescence intensity levels for each dose at each time point were analyzed using a one or two way analysis of variance (ANOVA) and Tukey's post-hoc analysis for multiple comparisons using GraphPad Prism 9.0. All data are presented as mean \pm standard error of mean (SEM).

Test article

The AAV5-*hRORA* drug product and formulation buffer consisting of 10 mM sodium phosphate, 180 mM sodium chloride, and 0.001% Poloxamer 188 (PF-68, Landrau Scientific Innovations, Leominster, MA, USA) at a pH of

7.3 ± 0.5 were supplied by Ocugen Inc. (Malvern, PA, USA). The intended doses (1×10^8 , 1×10^9 , and 4×10^9 vg/eye) were prepared for treatment and randomized. AAV5 was selected as a viral vector based on its safety and transduction efficiency in photoreceptors and RPE cells [51].

Subretinal injections

Abca4^{-/-} mice were given a subretinal injection with one of the three different doses of AAV5-*hRORA*. As a control, B6 mice were given a subretinal injection with AAV5-*hRORA*-GFP at 1 month (1M) of age. Mice were anesthetized with ketamine/xylazine. An incision was made in the sclera adjacent to the cornea using a 30 G needle. Slight resistance indicated that the Bruch's membrane had been breached. 0.5 μ l of the therapeutic was administered using a Hamilton syringe with a blunt cannula (33 G) where the cut was made using a 30 G needle, into the subretinal space. Only the right eye was treated, and the left eye was either left uninjected, or an incision was made (mock) or injected with the formulation buffer (mock + buffer).

Genotyping

DNA was isolated from mouse tail biopsy samples by lysing the samples using sodium hydroxide method. DNA samples were amplified using the following primers: the common forward primer, AGG AGA AGC AAT CAA ATC AGG A; the WT reverse, GAA GAT GCT CTG GAT ATC TCT GC; and the mutant reverse primer, TGA GTA GGT GTC ATT CTA TTC TGG. The WT reverse primer amplifies a 4 kb region from the promoter and exon 1 of the *Abca4* gene, while the mutant reverse primer amplifies the neo cassette replacing this region [35, 52]. For PCR amplification, approximately 50 ng of DNA was used in a 10 μ l reaction consisting of 10x buffer that included MgCl₂, 40 mM of dNTP mix, 10 μ M of forward and reverse primer, and 5 U/mL of AmpliTaq DNA polymerase. Reactions were denatured at 94 °C for 2 min followed by 10 cycles at 94 °C for 30 s, 65 °C for 30 s with a reduction of 0.5 °C per cycle and 72 °C for 30 s, and then 28 cycles at 94 °C for 15 s, 60 °C for 30 s, 72 °C for 30 s and a final extension at 72 °C for 5 min. Amplified samples were separated by size using a 2% agarose gel and imaged under UV light after ethidium bromide staining. The WT amplicon is 123 base pairs long, and the mutant amplicon is 160 base pairs [35].

Blue light autofluorescence (BAF)

Fundus BAF imaging was used to measure the presence of lipofuscin as previously described [22], to test whether AAV5-*hRORA* treatment is able to resolve this phenotype. Animals were anesthetized with ketamine/xylazine by intraperitoneal (IP) injection, and 1% tropicamide was used for pupil dilation. BAF images were captured in response to light at 488 nm using a confocal scanning laser ophthalmoscope machine at the same light intensity, exposure and acquisition settings for all mice (Spectralis, Heidelberg, Germany).

Electroretinogram (ERG) analysis

Full field ERG. Scotopic and photopic ERGs were acquired as previously described [46, 53, 54] to measure retinal function (Diagnosys LLC, Lowell, MA, USA). Mice were dark adapted for at least 4 h to examine rod function through scotopic responses, and anesthetized via an IP injection of ketamine and xylazine diluted with saline. Gold loop electrodes were placed on the apex of the cornea for each eye. Silver needle electrodes were inserted subcutaneously in the bridge of the nose as a reference and in the base of the tail as a ground electrode. Responses to short wavelength flashes of light at 10 ms were acquired at 0.4 log intensity increments starting at an intensity of 0.000249 cd-s/m² up to 24.1 cd-s/m². Light-adapted responses were obtained similarly after 7 min of exposure to background light starting with an intensity of 0.1 cd-s/m² up to 25.6 cd-s/m² at 0.4 log intensity increments. The peak b-wave amplitude of AAV5-*hRORA*-treated *Abca4*^{-/-} mice was averaged and graphed in comparison to peak amplitude values from WT and untreated *Abca4*^{-/-} mice. The b-wave amplitude was also plotted over increasing log step intensity values in both treated and untreated *Abca4*^{-/-} mice compared with WT mice.

Recovery after photobleaching ERG. Mice were anesthetized using an IP administration of ketamine and xylazine mixed with saline, and were given another IP injection of ketamine at half of the original concentration when animals showed signs of awakening. After initial anesthesia, pupils were dilated and the baseline ERG waveform was acquired at 25 cd-s/m².

The retinas were subsequently photobleached using white light at 400 lux for 5 min, after which responses were recorded every 5 min at 25 cd-s/m² for 1 h [22, 23, 55]. The peak percentage recovery of all analyzed eyes were normalized to the peak of the 12951 control eyes, which was mathematically adjusted to 100%.

Histology

Histological analysis was carried out as described previously [54, 56, 57]. Eyes were collected, a cautery mark was made at the dorsal orientation of the eye and fixed in either methanol/acetic acid or 4% paraformaldehyde for paraffin embedding. After embedding, samples were sectioned (5 μ m/section) for hematoxylin and eosin (H&E) staining. Serial sections were collected at a similar depth in the central retina to reduce variability. Stained retinal sections were imaged on a DMI6000 Leica microscope (Wetzlar, Germany). The number of photoreceptor cell layers in the outer nuclear layer (ONL) were counted by a minimum of three double blinded personnel. The number of cell layers in the ONL was counted in three regions of the central retina at a similar retinal depth (~400 μ m), and compared between untreated *Abca4*^{-/-} retinas and *Abca4*^{-/-} eyes treated with three doses of AAV5-*hRORA* [46].

Immunohistochemistry (IHC)

IHC was performed as previously described [46]. Eyes collected for histology were also used for immunohistochemical analysis. Tissue sections of a similar retinal depth (~400 μ m) were deparaffinized, rehydrated, and 2% blocking serum applied for 1 h at room temperature, followed by incubation in primary antibody overnight. The CD59 antibody conjugated to FITC (mouse monoclonal, ab180633, Abcam, Waltham, MA, USA), the amyloid precursor protein (APP) antibody (rabbit polyclonal, 36-6900, Thermo Fisher, Waltham, MA, USA) and the RPE65 antibody (mouse monoclonal, MA1-16578, Thermo Fisher, Waltham, MA, USA) were used at a 1:100 dilution, and an antibody raised against RORA (rabbit, 101401, Genscript, Piscataway, NJ, USA) was used at a 1:500 dilution. An Alexa Fluor goat anti-rabbit or anti-mouse secondary antibody (A-21428, Thermo Fisher, Waltham, USA) was used to probe for the APP antibody or the RPE65 antibody, respectively. WT 12951 tissue was used as a reference for all doses. IHC slides were imaged on the DMI6000 Leica microscope. The mean fluorescence intensity of CD59 and RORA in the inner/outer segments (IS/OS) and RPE layers of WT, and untreated and AAV5-*hRORA*-treated *Abca4*^{-/-} retinas was evaluated using ImageJ [58] by manually selecting the IS/OS or RPE regions and measuring the mean gray levels.

Chromatin immunoprecipitation sequencing (ChIP-seq)

Putative target genes were analyzed for the *Rora* nuclear receptor binding site, (AGT)(TA)(AT)(TA)C(AT)AGGTCA, as previously described [48]. Binding sites were chosen at a maximum of 100 kilobases (kb) upstream of the start site of intron 1 for each gene. Retinas were dissected out from C57Bl/6 J mice, homogenized and fixed in 37% formaldehyde. The chromatin was sonicated to an average length of ~600 bp, followed by immunoprecipitation using 4 μ g of a RORA antibody (Thermo Fisher, PA1-812, Waltham, MA, USA) overnight at 4 °C. Samples were then incubated with Protein G dynabeads (10003D, Invitrogen, Waltham, MA, USA), and the beads were collected by centrifuging the samples at 10,000 rpm for 3 min, and washed in wash buffer and TE buffer. The protein-DNA complexes were eluted from the beads, and the cross links were removed using 200 mM NaCl. The chromatin DNA then underwent purification, and was sent for ChIP-seq (Harvard Bauer Core, Center for Systems Biology) and the data analyzed (Harvard Bioinformatics Core).

String pathway analysis

ChIP-seq data was further compared with AMD-linked pathways, including angiogenesis, lipid metabolism, inflammatory response, complement system and oxidative stress using String (version 10) [ref. 59]. Networks were created based on the connectivity between the genes. Each node depicts a protein encoded by the corresponding gene, and each line represents a functional or physical association between proteins. Known interactions are given in blue (curated databases), bright green (proteins mentioned together in publications) or pink lines (experimentally determined proteins), while predicted interactions are depicted in green (proteins in close proximity) or dark blue lines (co-occurring proteins).




Fig. 2 Reduced blue autofluorescence (BAF) (488 nm) in the fundus of AAV5-*hRORA* treated *Abca4*^{-/-} mice. **A** Fundus BAF images show increased AF levels in untreated *Abca4*^{-/-} mice compared with 129S1 (control) retinas, and a reduction in BAF in *Abca4*^{-/-} eyes treated with AAV5-*hRORA* at all three doses. **B** Quantification of autofluorescence as measured by mean gray levels shows a reduction in the BAF levels of *Abca4*^{-/-} eyes treated with either a low, mid or high dose of AAV5-*hRORA* at 1 month (1M), 3M and 6M post-treatment compared with untreated eyes at all ages studied. Mean \pm SEM, $n \geq 5$ biological replicates.




Fig. 3 Increased scotopic b-wave amplitudes in AAV5-*hRORA* treated *Abca4*^{-/-} mice. **A** Untreated 1M and 2M *Abca4*^{-/-} mice display a similar peak scotopic b-wave amplitude as control 129S1 mice. At 2M, eyes treated with AAV5-*hRORA* show a slight increase in the peak scotopic b-wave amplitude. There is a similar increase in peak scotopic b-wave amplitude at 4M and 7M in eyes treated with AAV5-*hRORA* compared with untreated eyes. **B** A statistically significant increase in scotopic b-wave amplitude was observed in AAV5-*hRORA* high dose-treated *Abca4*^{-/-} retinas at the highest intensity steps compared with untreated eyes at all ages tested ($p < 0.05$ to 0.0001). **C** The peak percent recovery of the baseline a-wave amplitude after photobleaching for 5 min at 400 lux exhibits a statistically significant increase in mid and high dose treated eyes compared with untreated eyes. Mean \pm SEM, $n \geq 5$ biological replicates.

RESULTS

Reduced BAF levels in AAV5-*hRORA*-treated *Abca4*^{-/-} retinas

RORA is a NHR that regulates numerous AMD-linked pathways, including angiogenesis, lipid metabolism and the inflammatory response pathways (Fig. 1). In particular, *RORA* regulates the inflammatory response and complement pathways that includes CD59, C3 and C5. Here, we evaluated *RORA* as a potent, broad-spectrum modifier gene therapy for macular degeneration using the *Abca4*^{-/-} mouse model. Distribution of *RORA* in the fundus was assessed by subretinal delivery of AAV5-*hRORA* tagged with GFP (AAV5-*hRORA*-GFP) into B6 mice. GFP was evaluated using BAF imaging, as this detects the presence of fluorescent particles excited by blue light at 488 nm, including GFP (Fig. S1). AAV5-*hRORA*-GFP was distributed throughout the fundus compared with the untreated B6 fundus. Moreover, no apparent adverse effects of treatment were observed on the fundus. Immunohistochemical evaluation of *RORA* was performed to determine expression in the retinal layers using WT (129S1) and *Abca4*^{-/-} tissue sections, which showed very little expression in untreated photoreceptor IS/OS, and RPE tissue compared with the WT strain (Fig. S2A, B). *Abca4*^{-/-} eyes treated with AAV5-*hRORA* showed a

significant elevation in *RORA* immunolabeling fluorescence intensity in the IS/OS (Fig. S2B, $p < 0.05$ to 0.0001) and RPE ($p < 0.01$ to 0.0001) at all three doses compared with untreated *Abca4*^{-/-} eyes.

AAV5-*hRORA*-treated *Abca4*^{-/-} mice were next evaluated using BAF fundus imaging to determine if *RORA* can rescue the dry AMD-like phenotype of lipofuscin deposits observed in *Abca4*^{-/-} mice [22, 50]. The effect of treatment was longitudinally assessed at 1M, 3M, and 6M post-treatment until the intermediate disease stage. Animals treated with AAV5-*hRORA* showed a reduction in the presence of subretinal deposits that was consistent across doses and ages examined (Fig. 2). Quantification of the levels showed that all three doses elicited a statistically significant reduction in BAF levels that is reflective of the amount of lipofuscin (Fig. 2B; $p < 0.05$ to 0.0001).

Improved photoreceptor function in AAV5-*hRORA*-treated *Abca4*^{-/-} mice

The effect of AAV5-*hRORA* treatment on photoreceptor function was subsequently evaluated in *Abca4*^{-/-} mice by using scotopic ERGs and testing recovery of photoreceptors after




Fig. 4 No adverse effects in *Abca4*^{-/-} retinas treated with AAV5-*hRORA*. **A** Histological analysis did not show a difference in the thickness of the retinal layers in the treated retinas compared with untreated eyes and the control background strain. **B** Quantification of the ONL layer number between untreated and AAV5-*hRORA*-treated *Abca4*^{-/-} mice showed no statistically significant change. GCL ganglion cell layer, INL inner nuclear layer, ONL outer nuclear layer; Mean \pm SEM, $n \geq 5$ biological replicates. Scale bars 50 μ m.




Fig. 5 Restored expression of CD59 in *Abca4*^{-/-} mice treated with the low, mid and high doses of AAV5-*hRORA*. **A** CD59 expression is observed in the inner/outer segments (IS, OS) (white arrows) of the photoreceptors and the retinal pigment epithelium (RPE) (insets, closed white arrowheads) in 4M and 7M 129S1 control retinas that is lacking in the untreated *Abca4*^{-/-} IS/OS region and RPE. CD59 expression is restored in AAV5-*hRORA* treated *Abca4*^{-/-} eyes in the IS/OS region (white arrows) and the RPE (insets, closed white arrowheads) at all three doses. Open arrowheads indicate autofluorescence in blood vessels. **B** There is a statistically significant increase in CD59 mean fluorescence intensity in both the photoreceptor IS/OS region ($p < 0.0001$) and the RPE ($p < 0.01$ to 0.0001) in *Abca4*^{-/-} eyes treated with all doses of AAV5-*hRORA* compared with untreated *Abca4*^{-/-} eyes. Mean \pm SEM; WT, $n \geq 3$ biological replicates; *Abca4*^{-/-}, $n \geq 5$ biological replicates. Scale bars 100 μ m.




Fig. 6 Reduced expression of amyloid precursor protein (APP) in AAV5-*hRORA*-treated *Abca4*^{-/-} mice. APP expression (green) was observed in the sub-RPE region of untreated *Abca4*^{-/-} eyes at 7M (2nd panel, outlined by dashed lines, arrows), while expression was attenuated in *Abca4*^{-/-} retinas treated with the mid dose of AAV5-*hRORA*. *n* = 5 biological replicates. Scale bars 100 μ m.

photobleaching. ERGs were performed up to 7M, as retinal degeneration phenotypes including lipofuscin deposits are apparent by this age [22]. The scotopic b-wave amplitudes were measured in AAV5-*hRORA*-treated *Abca4*^{-/-} animals to test the effect of AAV5-*hRORA* on photoreceptor function. ERG analysis of all three doses demonstrated a slight increase in peak scotopic b-wave amplitude in eyes treated with AAV5-*hRORA*. Prior studies on this mouse model show that the scotopic b-wave amplitude is within the normal range [22, 50]. However, high dose-treated *Abca4*^{-/-} eyes showed statistically significant improvement in the b-wave amplitude compared with untreated eyes (Fig. 3A, B; $p < 0.05$), and importantly, improvement was sustained until 7M of age (Fig. 3A, B). Moreover, there were no apparent adverse effects of AAV5-*hRORA* treatment on photoreceptor function.

Previous studies show that *Abca4*^{-/-} mice exhibit reduced recovery of scotopic a-wave amplitude after a photobleaching event when compared with control animals [23]. Analysis showed that AAV5-*hRORA*-treated eyes at the mid and high doses showed a statistically significant increase in peak percentage recovery of the baseline a-wave amplitude after photobleaching when compared with untreated eyes (Fig. 3C; $p < 0.01$ to 0.0001).

No apparent adverse effect of AAV5-*hRORA* treatment on *Abca4*^{-/-} retinal morphology

H&E staining was performed to examine the effect of *RORA* treatment on retinal morphology and to assess potential adverse effects. Histological staining demonstrated no gross adverse effect of treatment in AAV5-*hRORA* treated knockout animals when compared with 129S1 mice and untreated *Abca4*^{-/-} mice (Fig. 4), which is consistent with the lack of adverse effects on the fundus in B6 eyes treated with AAV5-*hRORA*-GFP (Fig. S1), and absence of adverse effects on photoreceptor function in AAV5-*hRORA*-treated *Abca4*^{-/-} eyes (Fig. 3A, B). Normal cell topography was observed in both untreated and AAV5-*hRORA*-treated *Abca4*^{-/-} retinas (Fig. 4A). The number of cell layers in the ONL was counted, which showed no statistically significant difference between untreated *Abca4*^{-/-} eyes and *Abca4*^{-/-} eyes treated with the three doses of AAV5-*hRORA* (Fig. 4B).

Molecular rescue of the inflammatory response in AAV5-*hRORA*-treated *Abca4*^{-/-} retinas

RORA regulates the inflammatory response pathway that includes complement pathway genes and is implicated in both the STGD and dry AMD-like phenotypes [34–37, 47]. In particular, CD59, an inhibitor of the MAC, is downregulated in both diseases and is part of the *RORA*-regulated inflammatory response pathway that also includes *ABCA4* [33, 36, 37]. IHC was performed for CD59 to determine if AAV5-*hRORA* can restore CD59 expression in *Abca4*^{-/-} mice. We observed restoration of CD59 expression in AAV5-*hRORA* treated animals in the photoreceptor IS/OS and RPE (Fig. 5A). Moreover, there was a statistically significant increase in CD59 immunolabeling fluorescence intensity in the photoreceptor IS/OS (Fig. 5B, $p < 0.0001$) and the RPE ($p < 0.01$) of AAV5-*hRORA*-treated *Abca4*^{-/-} eyes compared with untreated eyes. Treatment with AAV5-*hRORA* not only improved CD59 expression, but the expression was comparable to the WT expression levels. Rescue of the molecular phenotype is consistent with rescue of clinical retinal degeneration phenotypes, including attenuated lipofuscin. Amyloid- β is an inflammatory component of deposits found in AMD that is derived from APP [60–63]. Consequently, IHC was performed for APP, with the data showing reduced expression of this protein in the sub-RPE region of treated retinas when compared with untreated *Abca4*^{-/-} eyes (Fig. 6).

DISCUSSION

Nuclear hormone receptors regulate numerous retinal homeostatic pathways. In particular, *RORA* is implicated in AMD and is a key regulator of pathways perturbed in AMD disease, such as the complement system including complement C3 and C5 that are targets of recent FDA-approved drugs for dry AMD [27, 28, 46, 47]. In this study we test the potential of three different doses of AAV5-*hRORA* as a modifier gene therapy to treat macular degeneration in *Abca4*^{-/-} mice, as it is a model for both early onset STGD and late onset dry AMD, and exhibits subretinal deposits and reduced retinal function, as well as perturbation of complement genes [22, 33, 34, 37, 64, 65].

Our data demonstrated rescue of STGD and dry AMD-like retinal degeneration across multiple clinical, functional and molecular measures in *Abca4*^{-/-} mice. BAF imaging showed clinical restoration reflecting a reduction in the level of lipofuscin and other deposits [43, 65, 66] at all time points in *Abca4*^{-/-} mice treated with AAV5-*hRORA*, with a more pronounced rescue at the mid and high doses. *Abca4* is an ATP-binding cassette transporter responsible for clearing the bisretinoid A2E, a toxic byproduct of the phototransduction cycle and the major fluorophore found in lipofuscin that emits autofluorescence picked up by BAF imaging [67]. A2E accumulation in the RPE prevents cholesterol efflux from RPE cells [68] and leads to RPE cell degeneration, eventually

causing photoreceptor loss and functional deficits [23]. According to Zhang et al., vitamin A byproducts such as A2E may compete with vitamin A, even binding to RPE65 and retinoic acid receptor [69]. This could then inhibit opsins, interfering with the phototransduction cycle and leading to delayed dark adaptation [69]. The reduction in BAF levels reflecting lipofuscin deposition in *RORA*-treated *Abca4*^{-/-} retinas is likely responsible for the observed improvement in functional recovery of photoreceptors after exposure to high-intensity light. The scotopic b-wave amplitude in untreated *Abca4*^{-/-} eyes are within the normal range until a later age [22]; however, there is a statistically significant elevation in b-wave amplitude in high dose-treated eyes, demonstrating that AAV5-*hRORA* treatment improves retinal function. Importantly, this improvement in function was sustained at 7M, and there were no observed adverse effects of *RORA* treatment on photoreceptor function.

In addition to clinical and functional improvements, the current study also demonstrated rescue of the molecular phenotype in *Abca4*^{-/-} mice. Restoration of CD59 expression in AAV5-*hRORA*-treated retinas suggests that the mechanism of action underpinning the observed functional and clinical improvements involves the complement pathway. A previous study showed that vitamin A byproducts, such as A2E, could interfere with CD59 recycling upon MAC activation, leading to its reduced expression in *Abca4*^{-/-} mice [37]. In the current study, regulation of the inflammatory response pathway by *RORA* is likely resulting in the observed restoration of CD59 expression, counteracting MAC activation. The attenuated inflammatory response could potentially lead to reduced presence of lipofuscin, as well as APP, the precursor for amyloid- β , a protein that increases inflammation and is normally found in human AMD deposits [60–63, 70, 71]. The APP antibody used in the current study potentially probes for both pathological amyloid- β , in addition to non-pathological APP. Expression of APP in the IS/OS observed in the current study could reflect accumulation of amyloid- β due to aging as demonstrated in previous animal studies [72–74]. On the other hand, APP expression observed in the inner retinal layers is likely because of its role in normal function in these layers [75].

RORA regulates numerous pathways associated with AMD, such as the angiogenesis pathway including FLT1 and VEGFA, the lipid metabolism pathway including ABCA1 and ABCA4, as well as the inflammatory response and complement pathways that include CD59, C3 and C5 (Fig. 1) [refs. 2, 46, 47, 76, 77]. The molecular phenotype in *Abca4*^{-/-} mice, including reduced CD59 and *RORA* expression, presents much earlier than and likely leads to the clinical phenotype [22, 37]. Downregulated *RORA* expression in *Abca4*^{-/-} mice impacts the pathways required for retinal function and homeostasis, leading to vision loss [2, 46, 47, 76]. The impact of these studies is that treatment with *RORA* before manifestation of the clinical phenotype potentially resets *RORA*-regulated pathways, including the inflammatory response pathway by restoring CD59 expression, thereby preventing disease.

In summary, this study was performed to evaluate efficacy of *RORA* as a modifier gene therapy for macular degeneration. AAV5-*hRORA* rescues STGD and dry AMD-like retinal degeneration, and improves retinal function and molecular outcomes in *Abca4*^{-/-} mice treated at the early to intermediate stage of disease. Interestingly, AAV5-*hRORA* treatment attenuated accumulation of both A2E, the phototransduction waste product that damages RPE cells, as well as APP, the precursor to amyloid- β implicated in pathogenesis in retinal and neurodegenerative diseases [60, 63, 78]. This attenuation, combined with restored expression of the MAC inhibitor, CD59, likely leads to the observed improvement in photoreceptor function. Importantly, no overt evidence of toxicity or abnormal structural changes in the retinas of treated mice was observed. Future studies will examine the longitudinal effect of AAV5-*hRORA* treatment on late-stage retinal degeneration in *Abca4*^{-/-} mice. AMD disease disrupts numerous

pathways essential for retinal homeostasis, including inflammation, oxidative stress, lipid metabolism and the complement pathway, which *RORA* regulates [2, 46, 47, 76]. Rescue of retinal degeneration in *Abca4*^{-/-} mice demonstrates the efficacy of *RORA* at resetting multiple disease pathways. Importantly, these studies demonstrate the effectiveness of *RORA* in treating both early-onset STGD and late-onset dry AMD, as mutations in *ABCA4* are observed in both diseases [30–32, 39]. Overall, the data demonstrates that AAV5-*hRORA* has the potential to be a powerfully effective one-time curative modifier gene therapy. *RORA* could be a broad-spectrum treatment for multiple forms of macular degeneration [45]. Two clinical trials are currently ongoing that evaluate the efficacy of *RORA* as a modifier gene therapy in different forms of macular degeneration, including dry AMD (NCT06018558) and STGD (NCT05956626).

DATA AVAILABILITY

All data used in this paper has been presented in the figures.

REFERENCES

- Fritsche LG, Igl W, Bailey JN, Grassmann F, Sengupta S, Bragg-Gresham JL, et al. A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. *Nat Genet.* 2016;48:134–43.
- Silveira AC, Morrison MA, Ji F, Xu H, Reinecke JB, Adams SM, et al. Convergence of linkage, gene expression and association data demonstrates the influence of the RAR-related orphan receptor alpha (*RORA*) gene on neovascular AMD: a systems biology based approach. *Vis Res.* 2010;50:698–715.
- Heesterbeek TJ, Lores-Motta L, Hoyng CB, Lechanteur YTE, den Hollander AI. Risk factors for progression of age-related macular degeneration. *Ophthalmic Physiol Opt.* 2020;40:140–70.
- DeAngelis MM, Owen LA, Morrison MA, Morgan DJ, Li M, Shakoob A, et al. Genetics of age-related macular degeneration (AMD). *Hum Mol Genet.* 2017;26:R45–R50.
- Morrison MA, Silveira AC, Huynh N, Jun G, Smith SE, Zacharakis F, et al. Systems biology-based analysis implicates a novel role for vitamin D metabolism in the pathogenesis of age-related macular degeneration. *Hum Genom.* 2011;5:538–68.
- Chen Y, Bedell M, Zhang K. Age-related macular degeneration: genetic and environmental factors of disease. *Mol Inter.* 2010;10:271–81.
- Xue W, Li JJ, Zou Y, Zou B, Wei L. Microbiota and ocular diseases. *Front Cell Infect Microbiol.* 2021;11:759333.
- Pennesi ME, Neuringer M, Courtney RJ. Animal models of age related macular degeneration. *Mol Asp Med.* 2012;33:487–509.
- Schultz NM, Bhardwaj S, Barclay C, Gaspar L, Schwartz J. Global burden of dry age-related macular degeneration: a targeted literature review. *Clin Ther.* 2021;43:1792–818.
- Maeda T, Sugita S, Kurimoto Y, Takahashi M. Trends of stem cell therapies in age-related macular degeneration. *J Clin Med.* 2021;10:1785.
- Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. *Lancet Glob Health.* 2014;2:e106–16.
- Di Carlo E, Augustin AJ. Prevention of the onset of age-related macular degeneration. *J Clin Med.* 2021;10:3297.
- Fujinami K, Lois N, Davidson AE, Mackay DS, Hogg CR, Stone EM, et al. A longitudinal study of stargardt disease: clinical and electrophysiologic assessment, progression, and genotype correlations. *Am J Ophthalmol.* 2013;155:1075–88.e13.
- Molday RS. Insights into the molecular properties of ABCA4 and its role in the visual cycle and stargardt disease. *Prog Mol Biol Transl Sci.* 2015;134:415–31.
- Strauss RW, Ho A, Muñoz B, Cideciyan AV, Sahel JA, Sunness JS, et al. The natural history of the progression of atrophy secondary to Stargardt disease (ProgStar) studies: design and baseline characteristics: progstar report No. 1. *Ophthalmology.* 2016;123:817–28.
- Burke TR, Tsang SH. Allelic and phenotypic heterogeneity in ABCA4 mutations. *Ophthalmic Genet.* 2011;32:165–74.
- Lambertus S, van Huet RA, Bax NM, Hoefsloot LH, Cremers FP, Boon CJ, et al. Early-onset Stargardt disease: phenotypic and genotypic characteristics. *Ophthalmology.* 2015;122:335–44.
- Georgiou M, Kane T, Tanna P, Bouzia Z, Singh N, Kalitzeos A, et al. Prospective cohort study of childhood-onset stargardt disease: fundus autofluorescence

- imaging, progression, comparison with adult-onset disease, and disease symmetry. *Am J Ophthalmol*. 2020;211:159–75.
19. Westeneng-van Haaften SC, Boon CJ, Cremers FP, Hoefsloot LH, den Hollander AL, Hoyng CB. Clinical and genetic characteristics of late-onset Stargardt's disease. *Ophthalmology*. 2012;119:1199–210.
 20. Oluleye TS, Aina AS, Sarimiye TF, Olaniyan SI. Stargardt's disease in two Nigerian siblings. *Int Med Case Rep J*. 2013;6:13–5.
 21. Pfau M, Holz FG, Muller PL. Retinal light sensitivity as outcome measure in recessive Stargardt disease. *Br J Ophthalmol*. 2021;105:258–64.
 22. Charbel Issa P, Barnard AR, Singh MS, Carter E, Jiang Z, Radu RA, et al. Fundus autofluorescence in the Abca4(-/-) mouse model of Stargardt disease—correlation with accumulation of A2E, retinal function, and histology. *Invest Ophthalmol Vis Sci*. 2013;54:5602–12.
 23. Mata NL, Tzekov RT, Liu X, Weng J, Birch DG, Travis GH. Delayed dark-adaptation and lipofuscin accumulation in abcr+/- mice: implications for involvement of ABCR in age-related macular degeneration. *Invest Ophthalmol Vis Sci*. 2001;42:1685–90.
 24. Fishman GA, Farbman JS, Alexander KR. Delayed rod dark adaptation in patients with Stargardt's disease. *Ophthalmology*. 1991;98:957–62.
 25. Vandenbroucke T, Buyl R, De Zaeytjij J, Bauwens M, Uvijls A, De Baere E, et al. Colour vision in Stargardt disease. *Ophthalmic Res*. 2015;54:181–94.
 26. Hu J, Pauer GJ, Hagstrom SA, Bok D, DeBenedictis MJ, Bonilha VL, et al. Evidence of complement dysregulation in outer retina of Stargardt disease donor eyes. *Redox Biol*. 2020;37:101787.
 27. Liao DS, Grossi FV, El Mehdi D, Gerber MR, Brown DM, Heier JS, et al. Complement C3 inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: a randomized phase 2 trial. *Ophthalmology*. 2020;127:186–95.
 28. Jaffe GJ, Westby K, Csaky KG, Mones J, Pearlman JA, Patel SS, et al. C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal phase 2/3 trial. *Ophthalmology*. 2021;128:576–86.
 29. Khan H, Aziz AA, Sulahria H, Khan H, Ahmed A, Choudhry N, et al. Emerging treatment options for geographic atrophy (GA) secondary to age-related macular degeneration. *Clin Ophthalmol*. 2023;17:321–7.
 30. Allikmets R, Shroyer NF, Singh N, Seddon JM, Lewis RA, Bernstein PS, et al. Mutation of the Stargardt disease gene (ABCR) in age-related macular degeneration. *Science*. 1997;277:1805–7.
 31. Fritsche LG, Fleckenstein M, Fiebig BS, Schmitz-Valckenberg S, Bindewald-Wittich A, Keilhauer CN, et al. A subgroup of age-related macular degeneration is associated with mono-allelic sequence variants in the ABCA4 gene. *Invest Ophthalmol Vis Sci*. 2012;53:2112–8.
 32. Shroyer NF, Lewis RA, Yatsenko AN, Wensel TG, Lupski JR. Cosegregation and functional analysis of mutant ABCR (ABCA4) alleles in families that manifest both Stargardt disease and age-related macular degeneration. *Hum Mol Genet*. 2001;10:2671–8.
 33. Moreno-Garcia A, Kun A, Calero O, Medina M, Calero M. An overview of the role of lipofuscin in age-related neurodegeneration. *Front Neurosci*. 2018;12:464.
 34. Ebrahimi KB, Fijalkowski N, Cano M, Handa JT. Decreased membrane complement regulators in the retinal pigmented epithelium contributes to age-related macular degeneration. *J Pathol*. 2013;229:729–42.
 35. Jabri Y, Biber J, Diaz-Lezana N, Grosche A, Pauly D. Cell-type-specific complement profiling in the ABCA4(-/-) mouse model of stargardt disease. *Int J Mol Sci*. 2020;21:8468.
 36. Kumar-Singh R. The role of complement membrane attack complex in dry and wet AMD - From hypothesis to clinical trials. *Exp Eye Res*. 2019;184:266–77.
 37. Tan LX, Toops KA, Lakkaraju A. Protective responses to slyblytic complement in the retinal pigment epithelium. *Proc Natl Acad Sci USA*. 2016;113:8789–94.
 38. Michaelides M, Chen LL, Brantley MA Jr., Andorf JL, Isaak EM, Jenkins SA, et al. ABCA4 mutations and discordant ABCA4 alleles in patients and siblings with bull's-eye maculopathy. *Br J Ophthalmol*. 2007;91:1650–5.
 39. Kjellstrom U, Andreasson S. A five-year follow-up of ABCA4 carriers showing deterioration of retinal function and increased structural changes. *Mol Vis*. 2022;28:300–16.
 40. Allikmets R, Singh N, Sun H, Shroyer NF, Hutchinson A, Chidambaram A, et al. A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive Stargardt macular dystrophy. *Nat Genet*. 1997;15:236–46.
 41. Fujinami K, Zernant J, Chana RK, Wright GA, Tsunoda K, Ozawa Y, et al. ABCA4 gene screening by next-generation sequencing in a British cohort. *Invest Ophthalmol Vis Sci*. 2013;54:6662–74.
 42. Zernant J, Schubert C, Im KM, Burke T, Brown CM, Fishman GA, et al. Analysis of the ABCA4 gene by next-generation sequencing. *Invest Ophthalmol Vis Sci*. 2011;52:8479–87.
 43. Cideciyan AV, Aleman TS, Swider M, Schwartz SB, Steinberg JD, Brucker AJ, et al. Mutations in ABCA4 result in accumulation of lipofuscin before slowing of the retinoid cycle: a reappraisal of the human disease sequence. *Hum Mol Genet*. 2004;13:525–34.
 44. Pellegrini M, Acquistapace A, Oldani M, Cereda MG, Giani A, Cozzi M, et al. Dark atrophy: an optical coherence tomography angiography study. *Ophthalmology*. 2016;123:1879–86.
 45. Runhart EH, Valkenburg D, Cornelis SS, Khan M, Sangermano R, Albert S, et al. Late-onset Stargardt disease due to mild, deep-intronic ABCA4 alleles. *Invest Ophthalmol Vis Sci*. 2019;60:4249–56.
 46. Li S, Datta S, Brabbit E, Love Z, Woytowicz V, Flattery K, et al. Nr2e3 is a genetic modifier that rescues retinal degeneration and promotes homeostasis in multiple models of retinitis pigmentosa. *Gene Ther*. 2021;28:223–41.
 47. Liu CH, Yemany F, Bora K, Kushwah N, Blomfield AK, Kamenecka TM, et al. Genetic deficiency and pharmacological modulation of RORalpha regulate laser-induced choroidal neovascularization. *Aging*. 2023;15:37–52.
 48. Olivares AM, Jelcick AS, Reinecke J, Leehy B, Haider A, Morrison MA, et al. Multimodal regulation orchestrates normal and complex disease states in the retina. *Sci Rep*. 2017;7:690.
 49. Jun G, Nicolaou M, Morrison MA, Buros J, Morgan DJ, Radeke MJ, et al. Influence of ROBO1 and RORA on risk of age-related macular degeneration reveals genetically distinct phenotypes in disease pathophysiology. *PLoS ONE*. 2011;6:e25775.
 50. Charbel Issa P, Barnard AR, Herrmann P, Washington I, MacLaren RE. Rescue of the Stargardt phenotype in Abca4 knockout mice through inhibition of vitamin A dimerization. *Proc Natl Acad Sci USA*. 2015;112:8415–20.
 51. Lotery AJ, Yang GS, Mullins RF, Russell SR, Schmidt M, Stone EM, et al. Adeno-associated virus type 5: transduction efficiency and cell-type specificity in the primate retina. *Hum Gene Ther*. 2003;14:1663–71.
 52. Weng J, Mata NL, Azarian SM, Tzekov RT, Birch DG, Travis GH. Insights into the function of Rim protein in photoreceptors and etiology of Stargardt's disease from the phenotype in ABCR knockout mice. *Cell*. 1999;98:13–23.
 53. Jelcick AS, Yuan Y, Leehy BD, Cox LC, Silveira AC, Qiu F, et al. Genetic variations strongly influence phenotypic outcome in the mouse retina. *PLoS ONE*. 2011;6:e21858.
 54. Mollema NJ, Yuan Y, Jelcick AS, Sachs AJ, von Alpen D, Schorderet D, et al. Nuclear receptor Rev-erb alpha (Nr1d1) functions in concert with Nr2e3 to regulate transcriptional networks in the retina. *PLoS ONE*. 2011;6:e17494.
 55. Kinoshita J, Peachey NS. Noninvasive electroretinographic procedures for the study of the mouse retina. *Curr Protoc Mouse Biol*. 2018;8:1–16.
 56. Cruz NM, Yuan Y, Leehy BD, Baid R, Kompella U, DeAngelis MM, et al. Modifier genes as therapeutics: the nuclear hormone receptor Rev Erb alpha (Nr1d1) rescues Nr2e3 associated retinal disease. *PLoS ONE*. 2014;9:e87942.
 57. Haider NB, Zhang W, Hurd R, Ikeda A, Nystruen AM, Naggert JK, et al. Mapping of genetic modifiers of Nr2e3 rd7/rd7 that suppress retinal degeneration and restore blue cone cells to normal quantity. *Mamm Genome*. 2008;19:145–54.
 58. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. *Nat Methods*. 2012;9:671–5.
 59. Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. *Nucleic Acids Res*. 2015;43:D447–52.
 60. Liu RT, Gao J, Cao S, Sandhu N, Cui JZ, Chou CL, et al. Inflammatory mediators induced by amyloid-beta in the retina and RPE in vivo: implications for inflammation activation in age-related macular degeneration. *Invest Ophthalmol Vis Sci*. 2013;54:2225–37.
 61. Huang H, Lennikov A. CXCR5/NRF2 double knockout mice develop retinal degeneration phenotype at early adult age. *Exp Eye Res*. 2020;196:108061.
 62. Lennikov A, Saddala MS, Mukwaya A, Tang S, Huang H. Autoimmune-mediated retinopathy in cxcr5-deficient mice as the result of age-related macular degeneration associated proteins accumulation. *Front Immunol*. 2019;10:1903.
 63. Anderson DH, Talaga KC, Rivest AJ, Barron E, Hageman GS, Johnson LV. Characterization of beta amyloid assemblies in drusen: the deposits associated with aging and age-related macular degeneration. *Exp Eye Res*. 2004;78:243–56.
 64. Chen Y, Roorda A, Duncan JL. Advances in imaging of Stargardt disease. *Adv Exp Med Biol*. 2010;664:333–40.
 65. Ly A, Nivison-Smith L, Assaad N, Kalloniatis M. Fundus autofluorescence in age-related macular degeneration. *Optom Vis Sci*. 2017;94:246–59.
 66. Al-Zamil WM, Yassin SA. Recent developments in age-related macular degeneration: a review. *Clin Inter Aging*. 2017;12:1313–30.
 67. Dyka FM, Molday LL, Chiodo VA, Molday RS, Hauswirth WW. Dual ABCA4-AAV vector treatment reduces pathogenic retinal A2E accumulation in a mouse model of autosomal recessive stargardt disease. *Hum Gene Ther*. 2019;30:1361–70.
 68. Lakkaraju A, Finnemann SC, Rodriguez-Boulan E. The lipofuscin fluorophore A2E perturbs cholesterol metabolism in retinal pigment epithelial cells. *Proc Natl Acad Sci USA*. 2007;104:11026–31.
 69. Zhang D, Robinson K, Saad L, Washington I. Vitamin A cycle byproducts impede dark adaptation. *J Biol Chem*. 2021;297:101074.

70. Zhao T, Gao J, Van J, To E, Wang A, Cao S, et al. Age-related increases in amyloid beta and membrane attack complex: evidence of inflammasome activation in the rodent eye. *J Neuroinflammation*. 2015;12:121.
71. Sun J, Huang P, Liang J, Li J, Shen M, She X, et al. Cooperation of Rel family members in regulating Abeta(1-40)-mediated pro-inflammatory cytokine secretion by retinal pigment epithelial cells. *Cell Death Dis*. 2017;8:e3115.
72. Hoh Kam J, Lenassi E, Jeffery G. Viewing ageing eyes: diverse sites of amyloid Beta accumulation in the ageing mouse retina and the up-regulation of macrophages. *PLoS ONE*. 2010;5:e13127.
73. Ning A, Cui J, To E, Ashe KH, Matsubara J. Amyloid-beta deposits lead to retinal degeneration in a mouse model of Alzheimer disease. *Invest Ophthalmol Vis Sci*. 2008;49:5136–43.
74. Zhang J, Gao F, Ma Y, Xue T, Shen Y. Identification of early-onset photoreceptor degeneration in transgenic mouse models of Alzheimer's disease. *iScience*. 2021;24:103327.
75. Ho T, Vessey KA, Cappai R, Dinet V, Mascarelli F, Ciccotosto GD, et al. Amyloid precursor protein is required for normal function of the rod and cone pathways in the mouse retina. *PLoS ONE*. 2012;7:e29892.
76. Tan PL, Bowes Rickman C, Katsanis N. AMD and the alternative complement pathway: genetics and functional implications. *Hum Genom*. 2016;10:23.
77. Olivares AM, Moreno-Ramos OA, Haider NB. Role of nuclear receptors in central nervous system development and associated diseases. *J Exp Neurosci*. 2015;9:93–121.
78. Wang L, Mao X. Role of retinal amyloid-beta in neurodegenerative diseases: overlapping mechanisms and emerging clinical applications. *Int J Mol Sci*. 2021;22:2360.

ACKNOWLEDGEMENTS

We thank Dr. Neal Peachey for helping us develop and optimize the photobleaching ERG protocol. We thank Dr. Anton Lennikov for his scientific input into the manuscript. We thank Karina Malhotra for help with genotyping mice, and we acknowledge the SERI-MEE Morphology, Microscopy, and Animal Facilities for their services (NIH: National Eye Institute, Grant # P30EY003790).

AUTHOR CONTRIBUTIONS

MA, SMM, ZL, NN, NPMC, MOA, MW, AMO and BDL conducted experiments. ASJ, ZL and MA performed data analysis, while MA, PS and NBH prepared the manuscript. MA, PS, AKU, DFC and NBH revised the manuscript, and NBH conceived the study and supervised experimental protocols.

FUNDING

This work was supported by the following funding agencies: Ocugen Inc. (NBH) and American Macular Degeneration Foundation (NBH).

COMPETING INTERESTS

The authors declare no competing interests.

ETHICAL APPROVAL

This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institute of Health, as well as the Association for Research in Vision and Ophthalmology (ARVO) Statement for the Use of Animals in Ophthalmic and Vision Research.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41434-024-00455-z>.

Correspondence and requests for materials should be addressed to N. B. Haider.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024